Skip to content

Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes

A Prospective Study to Evaluate the Safety and Effectiveness of the Supracor Presbyopic Treatment Algorithm for Pseudophakic Eyes Using Lasik

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01387360
Acronym
SUPRACOR
Enrollment
33
Registered
2011-07-04
Start date
2011-06-30
Completion date
2014-10-31
Last updated
2015-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperopia, Myopia, Presbyopia

Keywords

Myopia, Hyperopia, Presbyopia, Pseudophakia, LASIK

Brief summary

This clinical study has been planned to determine the effectiveness of a special laser treatment intended to correct both near and distance vision in patients who have undergone previous cataract surgery.

Detailed description

This clinical study has been planned to evaluate the safety and effectiveness of the SUPRACOR presbyopic excimer laser treatment algorithm for near myopic and near hyperopic indications, with or without astigmatism, when performed on the cornea of pseudophakic eyes implanted with a monofocal IOL.

Interventions

DEVICESupracor

The presbyopic treatment consists of a standard treatment for distance vision and the procedure known as SUPRACOR addition to correct near vision. The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances.

Sponsors

Technolas Perfect Vision GmbH
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Subjects must be at least 45 years old * Subjects must read, understand, and sign an Informed Consent Form (ICF). * Subjects must be willing and able to return for scheduled follow-up examinations through 6 months after surgery. * Subjects must have undergone previous uncomplicated cataract surgery with monofocal IOL implant in the study eye at least 3 months prior to study enrollment. * Subjects must have up to +/- 2.0 (D) of absolute spherical myopia or hyperopia (not spherical equivalent), with up to +/- 2.0 D of refractive astigmatism (NOT corneal astigmatism) by manifest subjective refraction. The spherical equivalent must be no more than +/- 2.0 D. * Subjects who have be screened successfully for acceptance of the SUPRACOR simulation

Exclusion criteria

* Subjects for whom the combination of their baseline corneal thickness and the planned operative parameters for the LASIK procedure would result in less than 250 microns of remaining corneal thickness below the flap postoperatively. * Subjects for whom the preoperative assessment of the ocular topography indicates that one or both eyes are not suitable candidates for treatment based upon the suggested computer-simulated treatment plan (e.G. Keratoconus).

Design outcomes

Primary

MeasureTime frame
The percentage of treated eyes with a best corrected high contrast distance VA of 20/25 or better6M

Secondary

MeasureTime frame
The percentage of treated eyes within +/- 0.50D of target refraction6M
The percentage of treated eyes with an uncorrected high contrast near VA of 20/40 or better6M
Stability analysis: change of ≤ 1D MRSE between two consecutive post-op visits6M
Preservation of VA: Loss of more than 2 lines in BCVA for distance vision6M
The percentage of treated eyes within +/- 1.00D of target refraction6M
The percentage of treated eyes with an induced subjective manifest refraction cylinder not within +/- 2.00D6M
Cumulative incidence of AEs6M
Cumulative incidence subjective symptoms6M
The percentage of treated eyes with a best-distance corrected high contrast distance VA of 20/40 or better6M

Countries

Philippines

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026